| Anti-CSF1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers. Diego A. Pedroza, Ph.D.
diego.pedroza@bcm.edu
Xiang H-F. Zhang, Ph.D.; Jeffrey M. Rosen, Ph.D.
Keywords: TNBC, macrophages, tumor immune microenvironment, metastases |
| Optimized HER2 Chimeric Antigen Receptor T cells (CAR-Ts) for the treatment of HER2 expressing metastatic breast cancer Valentina Hoyos, M.D.
hoyos@bcm.edu
Diego Chamorro, M.D.; Natalie Chen, M.D., Ph.D.; Nataly Torrejon, M.D.; Saisha Nalawade, Ph.D.; Rachel Schiff, Ph.D.; Mothaffar Rimawi, M.D.
Keywords: CAR-T cells, Immunotherapy, HER2 |
| Resistance to TDxd in HER2+ breast cancer: Models, Mechanisms and Treatment implications Jamunarani Veeraraghavan, Ph.D.
rschiff@bcm.edu
Jamunarani Veeraraghavan, Ph.D.; Fu-Tien Liao, Ph.D.; Caroline Sabotta, MS; Lanfang Qin, Ph.D.; Sarmistha Nanda, MS; Mothaffar F. Rimawi, M.D.; C. Kent Osborne, M.D.; Rachel Schiff, Ph.D.
Keywords: TDxd, Resistance, HER2+ breast cancer, tucatinib, EGFR |
